Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer

Nature Genetics

Volumn 39, Issue 5, 2007, Pages 655-660

  Holst, Frederik ^a   Stahl, Phillip R ^a   Ruiz, Christian ^b   Hellwinkel, Olaf ^a   Jehan, Zeenath ^c   Wendland, Marc ^a   Lebeau, Annette ^a   Terracciano, Luigi ^b   Al Kuraya, Khawla ^c   Jänicke, Fritz ^a   Sauter, Guido ^a   Simon, Ronald ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR ALPHA; TAMOXIFEN;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CHROMOSOME 6Q; CONTROLLED STUDY; DNA MICROARRAY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE FREQUENCY; GENE IDENTIFICATION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MICROARRAY ANALYSIS; MONOTHERAPY; PRECANCER; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE; SURVIVAL TIME; TISSUE MICROARRAY;

BASE SEQUENCE; BREAST NEOPLASMS; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MOLECULAR SEQUENCE DATA; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS, DNA;

EID: 34247634643     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng2006     Document Type: Article

References (25)

1. Ferlay, J., Bray, F., Pisani, P & Parkin, D.M. GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide (IARC Press, Lyon, 2000).
2. Katzenellenbogen, B.S., Kendra, K.L., Norman, M.J. & Berthois, Y. Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens. Cancer Res. 47, 4355-4360 (1987).
3. Ip, M., Milholland, R.J., Rosen, F. & Kim, U. Mammary cancer: selective action of the estrogen receptor complex. Science 203, 361-363 (1979).
4. Rose, C. et al. Therapeutic effect of tamoxifen related to estrogen receptor level. Recent Results Cancer Res. 71, 134-141 (1980).
5. Sunderland, M.C. & Osborne, C.K. Tamoxifen in premenopausal patients with metastatic breast cancer: a review. J. Clin. Oncol. 9, 1283-1297 (1991).
6. Stierer, M. et al. Immunohistochemical and biochemical measurement of estrogen and progesterone receptors in primary breast cancer. Correlation of histopathology and prognostic factors. Ann. Surg. 218, 13-21 (1993).
7. Andersen, J. & Poulsen, H.S. Immunohistochemical estrogen receptor determination in paraffin-embedded tissue. Prediction of response to hormonal treatment in advanced breast cancer. Cancer 64, 1901-1908 (1989).
8. Wolmark, N. & Dunn, B.K. The role of tamoxifen in breast cancer prevention: issues sparked by the NSABP Breast Cancer Prevention Trial (P-1). Ann. NY Acad. Sci. 949, 99-108 (2001).
9. Pauletti, G., Godolphin, W., Press, M.F. & Slamon, D.J. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 13, 63-72 (1996).
10. Pegram, M.D. et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J. Clin. Oncol. 16, 2659-2671 (1998).
11. Ruiz, C. et al. Tissue microarrays for comparing molecular features with proliferation activity in breast cancer. Int. J. Cancer 118, 2190-2194 (2006).
12. Dybdal, N. et al. Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab. Breast Cancer Res. Treat. 93, 3-11 (2005).
13. Press, M.F. et al. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin. Cancer Res. 11, 6598-6607 (2005).
14. Sauter, G. et al. Heterogeneity of erbB-2 gene amplification in bladder cancer. Cancer Res. 53, 2199-2203 (1993).
15. Sauter, G., Moch, H., Gasser, T.C., Mihatsch, M.J. & Waldman, F.M. Heterogeneity of chromosome 17 and erbB-2 gene copy number in primary and metastatic bladder cancer. Cytometry 21, 40-46 (1995).
16. Simon, R. et al. Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. J. Natl. Cancer Inst. 93, 1141-1146 (2001).
17. Simon, R. et al. Amplification pattern of 12q13-q15 genes (MDM2, CDK4, GLI) in urinary bladder cancer. Oncogene 21, 2476-2483 (2002).
18. Al-Kuraya, K. et al. Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res. 64, 8534-8540 (2004).
19. Courjal, F. et al. Cyclin gene amplification and overexpression in breast and ovarian cancers: evidence for the selection of cyclin D1 in breast and cyclin E in ovarian tumors. Int. J. Cancer 69, 247-253 (1996).
20. Khan, S.A., Rogers, M.A., Khurana, K.K., Meguid, M.M. & Numann, P.J. Estrogen receptor expression in benign breast epithelium and breast cancer risk. J. Natl. Cancer Inst. 90, 37-42 (1998).
21. Shoker, B.S., Jarvis, C., Sibson, D.R., Walker, C. & Sloane, J.P. Oestrogen receptor expression in the normal and pre-cancerous breast. J. Pathol. 188, 237-244 (1999).
22. Harvey, J.M., Clark, G.M., Osborne, C.K. & Allred, D.C. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J. Clin. Oncol. 17, 1474-1481 (1999).
23. Koivisto, P. et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res. 57, 314-319 (1997).
24. Nessling, M. et al. Candidate genes in breast cancer revealed by microarray-based comparative genomic hybridization of archived tissue. Cancer Res. 65, 439-447 (2005).
25. Wagner, U. et al. Chromosome 8p deletions are associated with invasive tumor growth in urinary bladder cancer. Am. J. Pathol. 151, 753-759 (1997)